Exelixis, Inc. (EXEL): Free Cash Flow
$875.84M
Year ended 2026-01-02, Fiscal 2025
$1.17B
Trailing 12 months to 2026-07-03
+37.8%
3-year compound annual growth
+37.4%
5-year compound annual growth
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-01-02, Fiscal 2025 | $875.84M | +30.4% | 2026-02-10, From 2025-01-04 |
| 2025-01-03, Fiscal 2024 | $671.54M | +129.3% | 2026-02-10, From 2023-12-30 |
| 2023-12-29 | $292.86M | -12.6% | 2026-02-10, From 2022-12-31 |
| 2022-12-30 | $334.91M | -3.4% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $346.58M | +94.0% | 2024-02-06, From 2021-01-02 |
| 2021-01-01, Fiscal 2020 | $178.64M | -65.3% | 2023-02-07, From 2020-01-04 |
| 2020-01-03, Fiscal 2019 | $514.12M | +34.4% | 2022-02-18, From 2018-12-29 |
| 2018-12-28 | $382.42M | +164.7% | 2021-02-11, From 2018-01-01 |
| 2017-12-29 | $144.47M | -30.8% | 2020-02-25, From 2016-12-31 |
| 2016-12-30 | $208.70M | n/m | 2019-02-22, From 2016-01-02 |
| 2016-01-01, Fiscal 2015 | -$141.50M | n/m | 2018-02-26, From 2015-01-03 |
| 2014-12-31 | -$235.88M | n/m | 2017-02-27, From 2014-01-01 |
| 2013-12-31 | -$200.94M | n/m | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | -$125.86M | n/m | 2015-03-02, From 2012-01-01 |
| 2011-12-31 | -$160.22M | n/m | 2014-02-20, From 2011-01-01 |
| 2010-12-31 | -$102.86M | n/m | 2013-02-21, From 2010-01-01 |
| 2009-12-31 | -$20.50M | n/a | 2012-02-22, From 2009-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Exelixis, Inc. (EXEL) | 2026-01-02 | $875.84M | +30.4% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $453.28M | -10.5% |
| Moderna, Inc. (MRNA) | 2025-12-31 | -$2.06B | n/m |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $748.70M | +34.4% |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $644.59M | +37.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $263.22M | +2.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $344.90M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $93.90M | -37.3% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.05B | -24.7% |
Compare EXEL, QGEN, MRNA, NBIX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗